|
1.
|
Look AT: Oncogenic transcription factors
in the human acute leukemias. Science. 278:1059–1064. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lucansky V, Sobotkova E, Tachezy R,
Duskova M and Vonka V: DNA vaccination against bcr-abl-positive
cells in mice. Int J Oncol. 35:941–951. 2009.PubMed/NCBI
|
|
3.
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and
Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T,
Sohara Y, Sugiyama Y and Mano H: Identification of the transforming
EML4-ALK fusion gene in non-small cell lung cancer. Nature.
448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Verdorfer I, Fehr A, Bullerdiek J, Scholz
N, Brunner A, Krugmann J, Hager M, Haufe H, Mikuz G and Scholtz A:
Chromosomal imbalances, 11q21 rearrangement and MECT1-MAML2 fusion
transcript in mucoepidermoid carcinomas of the salivary gland.
Oncol Rep. 22:305–311. 2009.PubMed/NCBI
|
|
6.
|
Mano H: Non-solid oncogenes in solid
tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci.
99:2349–2355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Shinmura K, Kageyama S, Tao H, Bunai T,
Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa
H and Sugimura H: EML4-ALK fusion transcripts, but no NPM-, TPM3-,
CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung
carcinomas. Lung Cancer. 61:163–169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya
T, Ishida T and Mori M: EML4-ALK fusion transcript is not found in
gastrointestinal and breast cancers. Br J Cancer. 98:1536–1539.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Choi YL, Takeuchi K, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H,
Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y,
Ishikawa Y and Mano H: Identification of novel isoforms of the
EML4-ALK transforming gene in non-small cell lung cancer. Cancer
Res. 68:4971–4976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Perner S, Wagner PL, Demichelis F, Mehra
R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W,
Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H and Rubin
MA: EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia.
10:298–302. 2008.PubMed/NCBI
|
|
11.
|
Takeuchi K, Choi YL, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y,
Okumura S, Nakagawa K, Ishikawa Y and Mano H: Multiplex reverse
transcription-PCR screening for EML4-ALK fusion transcripts. Clin
Cancer Res. 14:6618–6624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Inamura K, Takeuchi K, Togashi Y, Hatano
S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K,
Soda M, Choi YL, Mano H and Ishikawa Y: EML4-ALK lung cancers are
characterized by rare other mutations, a TTF-1 cell lineage, an
acinar histology and young onset. Mod Pathol. 22:508–515. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Takeuchi K, Choi YL, Togashi Y, Soda M,
Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y,
Okumura S, Nakagawa K, Ishikawa Y and Mano H: KIF5B-ALK, a novel
fusion oncokinase identified by an immunohistochemistry-based
diagnostic system for ALK-positive lung cancer. Clin Cancer Res.
15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Martelli MP, Sozzi G, Hernandez L,
Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P,
Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta
M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri
SA and Falini B: EML4-ALK rearrangement in non-small cell lung
cancer and non-tumor lung tissues. Am J Pathol. 174:661–670. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes
M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J,
Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi
SP, Gu TL, Polakiewicz RD, Rush J and Comb MJ: Global survey of
phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Koivunen JP, Mermel C, Zejnullahu K,
Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas
R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux
JP, Engelman JA, Gray NS, Lee C, Meyerson M and Jänne PA: EML4-ALK
fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Clin Cancer Res. 14:4275–4283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Horn L and Pao W: EML4-ALK: honing in on a
new target in non-small cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac
LR, Kwak EL, Lynch TJ and Iafrate AJ: Clinical features and outcome
of patients with non-small cell lung cancer who harbor EML4-ALK. J
Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
McDermott U, Iafrate AJ, Gray NS, Shioda
T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L,
Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA and
Settleman J: Genomic alterations of anaplastic lymphoma kinase may
sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer
Res. 68:3389–3395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Shinmura K, Iwaizumi M, Igarashi H, Nagura
K, Yamada H, Suzuki M, Fukasawa K and Sugimura H: Induction of
centrosome amplification and chromosome instability in
p53-deficient lung cancer cells exposed to benzo[a]pyrene diol
epoxide (B[a]PDE). J Pathol. 216:365–374. 2008.PubMed/NCBI
|
|
21.
|
Soda M, Takada S, Takeuchi K, Choi YL,
Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y,
Sugiyama Y and Mano H: A mouse model for EML4-ALK-positive lung
cancer. Proc Natl Acad Sci USA. 105:19893–19897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tort F, Pinyol M, Pulford K, Roncador G,
Hernandez L, Nayach I, Kluin-Nelemans HC, Kluin P, Touriol C,
Delsol G, Mason D and Campo E: Molecular characterization of a new
ALK translocation involving moesin (MSN-ALK) in anaplastic large
cell lymphoma. Lab Invest. 81:419–426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Lamant L, Gascoyne RD, Duplantier MM,
Armstrong F, Raghab A, Chhanabhai M, Rajcan-Separovic E, Raghab J,
Delsol G and Espinos E: Non-muscle myosin heavy chain (MYH9): a new
partner fused to ALK in anaplastic large cell lymphoma. Genes
Chromosomes Cancer. 37:427–432. 2003. View Article : Google Scholar : PubMed/NCBI
|
